Medicines Australia starts new Code of Conduct review

26 September 2011

Pharma trade group Medicines Australia has commenced a Review of its Code of Conduct and invites public submissions. The news came just a couple of days after the local subsidiary of UK drugs giant GlaxoSmithKline challenged rivals to follow the company’s action in revealing payments made to physicians and health-related organizations.

The Medicines Australia Code of Conduct sets the standards of conduct for the activities of companies when engaged in the promotion of prescription products used under medical supervision as permitted by Australian legislation.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical